Department of Epidemiology, University of Pittsburgh, A542 Crabtree Hall, 130 DeSoto Street, Pittsburgh, Pennsylvania, 15261, USA.
Infect Agent Cancer. 2011 Dec 7;6:25. doi: 10.1186/1750-9378-6-25.
We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings.
In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later.
Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69).
Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.
我们之前报道过人疱疹病毒 8（HHV-8）血清抗体的存在与特立尼达和多巴哥男性筛查发现的前列腺癌之间存在横断面关联。在同一研究人群中，我们研究了 HHV-8 血清阳性与随后筛查发现的前列腺癌之间的关联。
在没有在初次直肠指检（DRE）和前列腺特异性抗原（PSA）筛查中发现前列腺癌的 40-81 岁男性中，采用病例-队列设计，测量了基线 HHV-8 血清阳性（针对 HHV-8 裂解抗原的改良免疫荧光测定）与 DRE 和 PSA 筛查 3 或 5 年后发现的前列腺癌之间的关联。
分析包括 486 名独特个体、96 例前列腺癌病例和 415 名随机选择的代表风险队列的受试者。通过设计，随机亚队列包含 25 例前列腺癌病例。在亚队列中，HHV-8 血清阳性率随年龄分组而增加（40-49 岁：3.5%，50-59 岁：13.6%，≥60 岁：22.9%）。在初次筛查时 PSA 升高（≥4.0ng/ml）的男性中，HHV-8 血清阳性率高于 PSA 非升高的男性（30.4%vs.9.9%血清阳性；粗比值比（OR）3.96，95%置信区间（CI）1.53-10.2；年龄调整 OR 2.42，95%CI 0.91-6.47）。HHV-8 血清阳性并未增加前列腺癌的发病风险（年龄调整的危险比（HR）0.88，95%CI 0.46-1.69）。
病例-队列分析并未发现 HHV-8 血清阳性与前列腺癌之间的关联。然而，分析结果揭示了 HHV-8 与 PSA（前列腺炎症的标志物）之间可能存在关联。HHV-8 血清阳性和 PSA 升高的同时发生可能解释了 HHV-8 与 PSA 筛查发现的前列腺癌之间的横断面关联。
